| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 12/06/2001 | WO2001092526A1 Human kcnq5 potassium channel, methods and compositions thereof |
| 12/06/2001 | WO2001092522A2 Human fgf-20 nucleic acids and polypeptides |
| 12/06/2001 | WO2001092491A2 Mammalian protein phosphatases identified by in-silico analysis |
| 12/06/2001 | WO2001092485A1 DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE |
| 12/06/2001 | WO2001092479A2 Method to determine the differentiation potential of a target cell |
| 12/06/2001 | WO2001092333A2 Use of adnf for enhancing learning and memory |
| 12/06/2001 | WO2001092332A1 Feline hepatocyte growth factor |
| 12/06/2001 | WO2001092308A2 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 12/06/2001 | WO2001092304A2 Transporters and ion channels |
| 12/06/2001 | WO2001092282A2 Methods and compositions for treating flaviviruses and pestiviruses |
| 12/06/2001 | WO2001092264A1 Adenosine a2a receptor antagonists |
| 12/06/2001 | WO2001092262A1 New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound |
| 12/06/2001 | WO2001092261A1 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof |
| 12/06/2001 | WO2001092260A1 4-(2-phenylthiazol-5-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof |
| 12/06/2001 | WO2001092259A1 1,4-diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof |
| 12/06/2001 | WO2001092258A1 Imidazoloisoquinolines |
| 12/06/2001 | WO2001092257A1 Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands |
| 12/06/2001 | WO2001092256A1 2,7-naphthyridine derivatives |
| 12/06/2001 | WO2001092253A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 12/06/2001 | WO2001092240A1 Novel n-substituted phenothiazines and their use as modulators of serine hydrolase enzymes |
| 12/06/2001 | WO2001092239A1 Biciclic cyclohexylamines and their use as nmda receptor antogonists |
| 12/06/2001 | WO2001092235A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| 12/06/2001 | WO2001092230A1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis |
| 12/06/2001 | WO2001092227A1 Chemical compounds |
| 12/06/2001 | WO2001092226A1 Heterocyclic analgesic compounds and method of use thereof |
| 12/06/2001 | WO2001092221A1 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds |
| 12/06/2001 | WO2001092218A2 Polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | WO2001092213A2 Excitatory amino acid receptor modulators |
| 12/06/2001 | WO2001092212A1 Excitatory amino acid receptor modulators |
| 12/06/2001 | WO2001092210A1 Compounds for modulating the rage receptor |
| 12/06/2001 | WO2001092204A1 Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
| 12/06/2001 | WO2001092202A1 Il-8 receptor antagonists |
| 12/06/2001 | WO2001091801A2 Methods of transducing neural cells using lentivirus vectors |
| 12/06/2001 | WO2001091793A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 12/06/2001 | WO2001091787A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | WO2001091783A2 Methods and compositions for producing a neurosalutary effect in a subject |
| 12/06/2001 | WO2001091780A1 Neuroprotective peptides |
| 12/06/2001 | WO2001091756A2 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders |
| 12/06/2001 | WO2001091754A1 Protein kinase inhibitors |
| 12/06/2001 | WO2001091750A1 Use of a celecoxib composition for fast pain relief |
| 12/06/2001 | WO2001091749A1 Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors |
| 12/06/2001 | WO2001091736A2 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| 12/06/2001 | WO2001091732A2 Medicament for combating respiratory depression |
| 12/06/2001 | WO2001091720A2 Preparation of injectable suspensions having improved injectability |
| 12/06/2001 | WO2001091682A1 Composition and applicator for topical substance delivery |
| 12/06/2001 | WO2001070683A3 3-substituted-4-pyrimidone derivatives |
| 12/06/2001 | WO2001056532A3 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 12/06/2001 | WO2001051474A3 Polypharmacophoric agents |
| 12/06/2001 | WO2001049673A3 Compounds and methods for modulation of estrogen receptors |
| 12/06/2001 | WO2001049638A3 A process for converting stereoisomers of sertraline into sertraline |
| 12/06/2001 | WO2001046392A3 Homologues of human heparanase and splice variants thereof |
| 12/06/2001 | WO2001042421A3 Long-term cell culture compositions and genetically modified animals derived therefrom |
| 12/06/2001 | WO2001041704A3 Method for the prevention and/or treatment of atherosclerosis |
| 12/06/2001 | WO2001039796A3 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| 12/06/2001 | WO2001034201A3 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 12/06/2001 | WO2001034138B1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 12/06/2001 | WO2001027630A3 Methods to identify compounds that modulate neuronal activity |
| 12/06/2001 | WO2001025257A3 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery |
| 12/06/2001 | WO2001021605A8 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food |
| 12/06/2001 | WO2001018042A3 Apoptosis proteins |
| 12/06/2001 | WO2001017999A3 Amino-triazolopyridine derivatives |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001012662A3 Membrane associated proteins |
| 12/06/2001 | WO2001001972A3 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 12/06/2001 | WO2001000193A3 Zinc ionophores as anti-apoptotic agents |
| 12/06/2001 | WO2000077233A3 Complement-resistant non-mammalian dna viruses and uses thereof |
| 12/06/2001 | WO2000077206A3 The myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | WO2000077018A3 Purine derivatives |
| 12/06/2001 | WO2000061750A3 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS |
| 12/06/2001 | US20010049449 Aromatic sulfonyl alpha-cycloamino hydroxamates and their use as MMP inhibitors |
| 12/06/2001 | US20010049446 C-C9-Heteroaryl, linked via C or N, substituted or unsubstitued by 1,3-substituents, substituted benzoylguanidine derivatives useful for treating ischemia, cardiac infarct, angina pectoris, and storke etc. |
| 12/06/2001 | US20010049442 Paroxetine compositions |
| 12/06/2001 | US20010049439 Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same |
| 12/06/2001 | US20010049435 Myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | US20010049391 Tramadol or a pharmaceutically acceptable derivative or salt thereof and a carrier |
| 12/06/2001 | US20010049375 Neutral antagonists and use thereof in treating drug abuse |
| 12/06/2001 | US20010049360 Betaglycan as an inhibin receptor and uses thereof |
| 12/06/2001 | US20010049353 Stimulating secretion of pancreatic juices |
| 12/06/2001 | US20010049348 Interaction of NMDA receptor with protein tyrosine phosphatase |
| 12/06/2001 | US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases |
| 12/06/2001 | DE10050267A1 Dental and/or oral cleaning agent, such as toothpaste, tooth gel, tooth powder, medicinal chewing gum, mouthwash, mouth powder, mouth pill or toothpick, comprises psychopharmaceutical |
| 12/06/2001 | DE10025644A1 Schmales bandförmiges transdermales therapeutisches System zur Applikation von Wirkstoffen direkt über dem arteriellen oder venösen Gefäßsystem Narrow band-shaped transdermal therapeutic system for the administration of active ingredients directly through the arterial or venous vascular system |
| 12/06/2001 | DE10025464A1 Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen Combined use of enzyme inhibitors for the therapy of autoimmune diseases, transplantation and tumor diseases as well as combinations of enzyme inhibitors pharmaceutical preparations comprising |
| 12/06/2001 | CA2599562A1 Compounds for modulating the rage receptor |
| 12/06/2001 | CA2411666A1 Methods and compositions for producing a neurosalutary effect in a subject |
| 12/06/2001 | CA2411323A1 Il-8 receptor antagonists |
| 12/06/2001 | CA2410935A1 Novel polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | CA2410912A1 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 12/06/2001 | CA2410903A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | CA2410762A1 Feline hepatocyte growth factor |
| 12/06/2001 | CA2410735A1 Use of adnf for enhancing learning and memory |
| 12/06/2001 | CA2410734A1 Dnas encoding mammalian histamine receptor of the h4 subtype |
| 12/06/2001 | CA2410684A1 Method to determine the differentiation potential of a target cell |
| 12/06/2001 | CA2410660A1 Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
| 12/06/2001 | CA2410650A1 Medicament for combating respiratory depression |
| 12/06/2001 | CA2410618A1 S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders |
| 12/06/2001 | CA2410489A1 Human kcnq5 potassium channel, methods and compositions thereof |
| 12/06/2001 | CA2410475A1 Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors |
| 12/06/2001 | CA2410453A1 Neuroprotective peptides |
| 12/06/2001 | CA2410087A1 Mammalian protein phosphatases identified by in-silico analysis |